Business
Immatics Announces First Quarter 2025 Financial Results and Business Update
IMA203 PRAME Cell Therapy: Randomized-controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing and expected to complete enrollment in 2026IMA203 PRAME Cell Therapy: Phase 1b clinical trial ongoing with updated data in metastatic melanoma with substantially longer follow-up and additional uveal melanoma patients to be presented in an oral presentation at the 2025 ASCO Annual Meeting IMA203CD8 PRAME Cell Therapy (GEN2): Phase 1a clinical trial in solid tumors ongoing with
About this update from Immatics N.v.
[{"type":"image","alt":"https://immatics.com/","displaySize":"","headline":null,"caption":"https://immatics.com/","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":111,"url":"https://media.zenfs.com/en/globenewswire.com/1304d6da4a2e1904f1143022249119ce"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GNZ6JLUt9xQWI9XKWr6tFw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1304d6da4a2e1904f1143022249119ce","width":300,"height":111}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"IMA203 PRAME Cell Therapy: Randomized-controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing and expected to complete enrollment in 2026","length":164,"tagName":"p"}]},{"val":[{"type":"text","content":"IMA203 PRAME Cell Therapy: Phase 1b clinical trial ongoing with updated data in metastatic melanoma with substantially longer follow-up and additional uveal melanoma patients to be presented in an oral presentation at the 2025 ASCO Annual Meeting ","length":246,"tagName":"p"}]},{"val":[{"type":"text","content":"IMA203CD8 PRAME Cell Therapy (GEN2): Phase 1a clinical trial in solid tumors ongoing with next data update, including dose escalation and ovarian cancer data, planned in 2025","length":174,"tagName":"p"}]},{"val":[{"type":"text","content":"IMA402 PRAME Bispecific: Phase 1a clinical trial in solid tumors ongoing with next data update at relevant dose levels planned in 2025","length":134,"tagName":"p"}]},{"val":[{"type":"text","content":"Combination of IMA203 PRAME cell therapy and Moderna’s PRAME adaptive immune modulating therapy: FDA granted IND clearance for a Phase 1 trial","length":142,"tagName":"p"}]},{"val":[{"type":"text","content":"IMA401 MAGEA4/8 Bispecific: Phase 1a clinical trial, including a checkpoint inhibitor combination, ongoing with next data update with a focus on head and neck cancer planned in 2025","length":181,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash and cash equivalents as well as other financial assets of $588.1 million1 (€543.8 million) as of March 31, 2025; cash reach into 2H 2027","length":141,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1182,"olType":false},{"type":"text","content":"Houston, Texas and Tuebingen, Germany, May 13, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the ...